JPS5990947A
(ja)
*
|
1982-11-16 |
1984-05-25 |
Matsushita Electronics Corp |
半導体装置
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US20040141983A1
(en)
*
|
1999-03-15 |
2004-07-22 |
Protein Design Labs, Inc. |
Compositions against cancer antigen LIV-1 and uses thereof
|
US7244827B2
(en)
|
2000-04-12 |
2007-07-17 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
US7358353B2
(en)
|
2000-08-22 |
2008-04-15 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
US7256257B2
(en)
*
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
PT2163256E
(pt)
|
2001-05-11 |
2015-11-20 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US20050272120A1
(en)
*
|
2001-06-20 |
2005-12-08 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20110045005A1
(en)
*
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
SG108837A1
(en)
|
2002-03-11 |
2005-02-28 |
Pi Eta Consulting Co Pte Ltd |
An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
JP4741838B2
(ja)
|
2002-07-31 |
2011-08-10 |
シアトル ジェネティクス,インコーポレーテッド |
癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
|
US20040081653A1
(en)
*
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
WO2004067564A2
(en)
*
|
2003-01-29 |
2004-08-12 |
Protein Design Labs, Inc. |
Compositions against cancer antigen liv-1 and uses thereof
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
US20080025989A1
(en)
*
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US7985401B2
(en)
|
2003-10-31 |
2011-07-26 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
PT2489364E
(pt)
*
|
2003-11-06 |
2015-04-16 |
Seattle Genetics Inc |
Compostos de monometilvalina conjugados com anticorpos
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
US7375078B2
(en)
*
|
2004-02-23 |
2008-05-20 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
AU2005218642B2
(en)
*
|
2004-03-02 |
2011-04-28 |
Seagen Inc. |
Partially loaded antibodies and methods of their conjugation
|
AU2004319915B9
(en)
|
2004-04-22 |
2011-12-22 |
Agensys, Inc. |
Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
AU2005294723A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Therapeutic agents with decreased toxicity
|
US7641903B2
(en)
*
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US7491390B2
(en)
|
2004-10-15 |
2009-02-17 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
ES2715776T3
(es)
*
|
2004-11-12 |
2019-06-06 |
Seattle Genetics Inc |
Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
|
WO2006060533A2
(en)
|
2004-12-01 |
2006-06-08 |
Genentech, Inc. |
Conjugates of 1, 8-bis-naphthalimides with an antibody
|
AU2006210837B2
(en)
*
|
2005-01-31 |
2012-07-12 |
Genentech, Inc. |
Anti-EphB2 antibodies and methods using same
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
EP3058955B1
(en)
*
|
2005-03-24 |
2019-05-29 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind ov064 and methods of use therefor
|
EP1871418B1
(en)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
KR20140084242A
(ko)
*
|
2005-06-20 |
2014-07-04 |
피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 |
Psma 항체-약물 접합체
|
USRE47223E1
(en)
*
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DK2135881T3
(da)
|
2005-06-20 |
2011-12-05 |
Genentech Inc |
Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
|
US20070003559A1
(en)
*
|
2005-07-01 |
2007-01-04 |
Wyeth |
Methods of determining pharmacokinetics of targeted therapies
|
WO2007008603A1
(en)
*
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
SI1912671T1
(en)
|
2005-07-18 |
2018-01-31 |
Seattle Genetics, Inc. |
Conjugates beta-glucuronide linker-drug
|
US8034765B2
(en)
|
2005-08-31 |
2011-10-11 |
Abraxis Bioscience, Llc |
Compositions and methods for preparation of poorly water soluble drugs with increased stability
|
CN101291659A
(zh)
|
2005-08-31 |
2008-10-22 |
阿布拉科斯生物科学有限公司 |
包含水难溶性药剂和抗微生物剂的组合物
|
AU2006294554B2
(en)
*
|
2005-09-26 |
2013-03-21 |
E. R. Squibb & Sons, L.L.C. |
Antibody-drug conjugates and methods of use
|
US8124738B2
(en)
*
|
2005-09-26 |
2012-02-28 |
Medarex, Inc. |
Human monoclonal antibodies to CD70
|
EP1942944A2
(en)
*
|
2005-10-31 |
2008-07-16 |
Genentech, Inc. |
Macrocyclic depsipeptide antibody-drug conjugates and methods
|
EP3006466B1
(en)
|
2005-12-02 |
2018-08-01 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
CA2630483C
(en)
*
|
2005-12-08 |
2015-05-19 |
Medarex, Inc. |
Human monoclonal antibodies to o8e
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
TWI478938B
(zh)
|
2006-01-20 |
2015-04-01 |
Genentech Inc |
抗-ephrinb2抗體及使用該抗體的方法
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
AR059900A1
(es)
|
2006-03-17 |
2008-05-07 |
Genentech Inc |
Anticuerpos anti-tat226 e inmunoconjugados
|
ES2363891T3
(es)
|
2006-03-20 |
2011-08-18 |
The Regents Of The University Of California |
Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
|
KR20140085544A
(ko)
|
2006-05-30 |
2014-07-07 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
EP2845912A1
(en)
|
2006-09-12 |
2015-03-11 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
|
DK2502938T3
(en)
|
2006-10-27 |
2015-04-20 |
Genentech Inc |
Antibodies and immunoconjugates and uses thereof
|
DK2099823T4
(da)
|
2006-12-01 |
2022-05-09 |
Seagen Inc |
Målbindingsmiddelvarianter og anvendelser deraf
|
AU2007333098A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
CN101711284A
(zh)
|
2007-01-25 |
2010-05-19 |
达娜-法勃肿瘤研究所 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Robo4 항체 및 그의 용도
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
EP2144628B1
(en)
|
2007-05-08 |
2012-10-17 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
BRPI0813514A2
(pt)
|
2007-07-16 |
2019-09-24 |
Genentech Inc |
anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
|
PT2474557E
(pt)
|
2007-07-16 |
2014-12-03 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
WO2009032949A2
(en)
*
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
JP5951929B2
(ja)
*
|
2007-10-03 |
2016-07-13 |
コーネル ユニヴァーシティー |
Psma抗体を用いる増殖性障害の治療
|
JP5727786B2
(ja)
|
2007-10-19 |
2015-06-03 |
シアトル ジェネティクス,インコーポレーテッド |
Cd19結合性物質およびその使用
|
MY188455A
(en)
*
|
2007-10-19 |
2021-12-09 |
Genentech Inc |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
CA2705486C
(en)
|
2007-11-19 |
2019-04-02 |
Celera Corporation |
Lung cancer markers and uses thereof
|
ES2613963T3
(es)
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
SI2247620T1
(sl)
|
2008-01-31 |
2016-09-30 |
Genentech, Inc. |
Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
|
CA2718942A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
EP2271770B1
(en)
*
|
2008-03-31 |
2018-08-22 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing asthma
|
ES2458541T3
(es)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
|
AR072804A1
(es)
|
2008-07-15 |
2010-09-22 |
Genentech Inc |
Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
|
JP5986745B2
(ja)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカAcademia Sinica |
Ptfe様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
WO2010027513A2
(en)
|
2008-09-08 |
2010-03-11 |
Psma Development Company, Llc |
Methods for killing psma-expressing, taxane-resistant cancer cells
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
WO2010081004A1
(en)
|
2009-01-09 |
2010-07-15 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
US8426398B2
(en)
|
2009-01-13 |
2013-04-23 |
Emory University |
Conjugates of noscapine and folic acid and their use in treating cancer
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
CA2752510C
(en)
*
|
2009-02-17 |
2024-01-23 |
Neil Bander |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
KR20120034591A
(ko)
*
|
2009-03-06 |
2012-04-12 |
어젠시스 인코포레이티드 |
24p4c12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
MX345909B
(es)
|
2009-03-25 |
2017-02-22 |
Genentech Inc |
Anticuerpos anti-fgfr3 y métodos que los utilizan.
|
MX2011010012A
(es)
|
2009-03-25 |
2011-12-06 |
Genentech Inc |
NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
|
RU2016110891A
(ru)
|
2009-04-01 |
2018-11-27 |
Дженентек, Инк. |
Антитела к fcrh5, их иммуноконъюгаты и способы их применения
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
JP5795759B2
(ja)
|
2009-04-16 |
2015-10-14 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗TNF−α抗体およびその用途
|
JP2012526839A
(ja)
|
2009-05-13 |
2012-11-01 |
シー レーン バイオテクノロジーズ, エルエルシー |
インフルエンザウイルスに対する中和分子
|
KR101763808B1
(ko)
|
2009-06-04 |
2017-08-16 |
노파르티스 아게 |
IgG 콘쥬게이션을 위한 자리의 확인 방법
|
SG10201403327WA
(en)
|
2009-06-17 |
2014-10-30 |
Abbvie Biotherapeutics Inc |
Anti-vegf antibodies and their uses
|
EP2445520A4
(en)
|
2009-06-22 |
2013-03-06 |
Medimmune Llc |
MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
|
US9808532B2
(en)
|
2009-07-15 |
2017-11-07 |
The Regents Of The University Of California |
Peptides whose uptake in cells is controllable
|
WO2011015920A2
(en)
*
|
2009-08-03 |
2011-02-10 |
Avesthagen Limited |
A highly efficient process of purification and production of recombinant trastuzumab
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
US8598345B2
(en)
*
|
2009-09-17 |
2013-12-03 |
Vanderbilt University |
Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
|
CA2775350A1
(en)
*
|
2009-09-24 |
2011-03-31 |
Seattle Genetics, Inc. |
Dr5 ligand drug conjugates
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
MX2012003198A
(es)
|
2009-10-23 |
2012-06-12 |
Millennium Pharm Inc |
Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados.
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
BR112012012887A2
(pt)
|
2009-12-02 |
2017-05-02 |
Imaginab Inc |
minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
CN102791738B
(zh)
|
2009-12-10 |
2015-10-07 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
PL2516465T3
(pl)
|
2009-12-23 |
2016-11-30 |
|
Przeciwciała anty-bv8 i ich zastosowania
|
MX2012008884A
(es)
|
2010-02-08 |
2012-08-31 |
Agensys Inc |
Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b.
|
EP2536748B1
(en)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011109308A1
(en)
*
|
2010-03-02 |
2011-09-09 |
Seattle Genetics, Inc. |
Methods for screening antibodies
|
EP2542587A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
EP2542588A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
CN102822198B
(zh)
|
2010-03-12 |
2016-08-31 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
MX2012011112A
(es)
|
2010-03-31 |
2012-10-15 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd40.
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
CA2795353C
(en)
|
2010-04-15 |
2018-01-09 |
Spirogen Developments Sarl |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
MX336109B
(es)
|
2010-06-03 |
2016-01-08 |
Genentech Inc |
Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
|
EP2579897A1
(en)
|
2010-06-08 |
2013-04-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
US8722629B2
(en)
|
2010-06-10 |
2014-05-13 |
Seattle Genetics, Inc. |
Auristatin derivatives and use thereof
|
ME02919B
(me)
*
|
2010-06-15 |
2018-04-20 |
Genmab As |
Konjugati humanog antitijela sa lijekom protiv tkivnog faktora
|
AR082017A1
(es)
|
2010-06-18 |
2012-11-07 |
Genentech Inc |
Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
CA2806855A1
(en)
|
2010-08-03 |
2012-02-09 |
F. Hoffmann - La Roche Ag |
Chronic lymphocytic leukemia (cll) biomarkers
|
BR112013003279A2
(pt)
|
2010-08-13 |
2016-06-14 |
Genentech In |
“métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
|
KR101673653B1
(ko)
|
2010-08-13 |
2016-11-08 |
로슈 글리카트 아게 |
항-fap 항체 및 이의 사용 방법
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
EP3264089A1
(en)
|
2010-08-31 |
2018-01-03 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
US8987209B2
(en)
|
2010-09-29 |
2015-03-24 |
Seattle Genetics, Inc. |
N-carboxyalkyl-auristatin and the use thereof
|
AU2011312417B2
(en)
|
2010-09-29 |
2015-08-20 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
EP2621954A1
(en)
|
2010-10-01 |
2013-08-07 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
AU2011316917B2
(en)
|
2010-10-22 |
2016-02-25 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
EA201390669A1
(ru)
|
2010-11-10 |
2013-11-29 |
Дженентек, Инк. |
Способы и композиции для иммунотерапии заболеваний нервной системы
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
PT3461847T
(pt)
|
2010-12-06 |
2020-12-24 |
Seagen Inc |
Anticorpos humanizados para liv-1 e uso dos mesmos para tratar cancro
|
EP2652498B1
(en)
|
2010-12-16 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Diagnosis and treatments relating to th2 inhibition
|
CA2819269A1
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
JP6162606B2
(ja)
|
2011-01-14 |
2017-07-12 |
レッドウッド バイオサイエンス, インコーポレイテッド |
アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
|
EP2670776B1
(en)
|
2011-02-04 |
2018-11-21 |
F. Hoffmann-La Roche AG |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CA2829736C
(en)
*
|
2011-03-16 |
2020-07-21 |
Seattle Genetics, Inc. |
N-carboxyalkylauristatins and use thereof
|
RS57895B1
(sr)
|
2011-03-29 |
2019-01-31 |
Roche Glycart Ag |
Fc varijante antitela
|
CA2831307A1
(en)
|
2011-03-30 |
2012-10-04 |
Arizona Board Of Regents, For And On Behalf Of, Arizona State Universi |
Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
|
RU2624141C2
(ru)
|
2011-04-01 |
2017-06-30 |
ВАЙЕТ ЭлЭлСи |
Конъюгаты "антитело-лекарственное средство"
|
JP2014516511A
(ja)
|
2011-04-07 |
2014-07-17 |
ジェネンテック, インコーポレイテッド |
抗fgfr4抗体及び使用方法
|
BR112013026423A2
(pt)
|
2011-04-20 |
2016-11-29 |
Roche Glycart Ag |
método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
JP2014515753A
(ja)
*
|
2011-04-21 |
2014-07-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
新規な結合剤−薬物複合体(adc)およびそれらの使用
|
JP6196613B2
(ja)
|
2011-05-08 |
2017-09-13 |
レゴケム バイオサイエンシズ, インク.Legochem Biosciences, Inc. |
タンパク質−活性剤コンジュゲートおよびこれを調製するための方法
|
EP2707020A4
(en)
|
2011-05-09 |
2015-01-14 |
Univ Virginia Patent Found |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
ES2567276T3
(es)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
|
PT2710035T
(pt)
|
2011-05-16 |
2017-06-05 |
Hoffmann La Roche |
Agonistas do fgfr1 e métodos de utilização
|
WO2012159027A2
(en)
|
2011-05-19 |
2012-11-22 |
President And Fellows Of Harvard College |
Osw-1 analogs and conjugates, and uses thereof
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
CN103702996A
(zh)
|
2011-05-27 |
2014-04-02 |
Ambrx公司 |
含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
|
CN113527414A
(zh)
*
|
2011-05-27 |
2021-10-22 |
Ambrx公司 |
含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
PL3415531T3
(pl)
|
2011-05-27 |
2024-02-26 |
Glaxo Group Limited |
Białka wiążące antygen
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
MX368966B
(es)
|
2011-06-10 |
2019-10-23 |
Mersana Therapeutics Inc |
Conjugados de proteina-polimero-farmaco.
|
EP2721049A1
(en)
|
2011-06-16 |
2014-04-23 |
Lonza Ltd |
A process for extraction of peptides and its application in liquid phase peptide synthesis
|
WO2012177647A2
(en)
|
2011-06-20 |
2012-12-27 |
Kerry Lane |
Mycotoxin diagnostics and methods thereof
|
KR20140037208A
(ko)
*
|
2011-06-21 |
2014-03-26 |
이뮤노젠 아이엔씨 |
펩타이드 링커를 갖는 신규한 메이탄시노이드 유도체 및 이의 접합체
|
AU2015224535B2
(en)
*
|
2011-06-21 |
2017-07-20 |
Immunogen, Inc. |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013016714A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
US9278144B2
(en)
|
2011-07-29 |
2016-03-08 |
Avelas Biosciences, Inc. |
Selective delivery molecules and methods of use
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
CN103781801B
(zh)
|
2011-08-23 |
2018-02-09 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
BR112014006703A8
(pt)
|
2011-09-20 |
2018-01-09 |
Spirogen Sarl |
"pirrolobenzodiazepinas
|
CA2845147A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
EP2764351B1
(en)
|
2011-09-29 |
2018-11-07 |
Seattle Genetics, Inc. |
Intact mass determination of protein conjugated agent compounds
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
AU2012323287B2
(en)
|
2011-10-10 |
2018-02-01 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
US9193766B2
(en)
|
2011-10-14 |
2015-11-24 |
Genentech, Inc. |
Peptide inhibitors of BACE1
|
EP2755642B1
(en)
|
2011-10-14 |
2018-07-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
AR088322A1
(es)
|
2011-10-14 |
2014-05-28 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
MX341523B
(es)
|
2011-10-14 |
2016-08-24 |
Medimmune Ltd |
Pirrolobenzodiazepinas.
|
KR101961976B1
(ko)
|
2011-10-14 |
2019-03-25 |
시애틀 지네틱스, 인크. |
피롤로벤조디아제핀 및 표적 접합체
|
EA027386B1
(ru)
|
2011-10-14 |
2017-07-31 |
Медимьюн Лимитед |
Пирролобензодиазепины
|
CN103998027A
(zh)
|
2011-10-15 |
2014-08-20 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的scd1拮抗剂
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
WO2013068874A1
(en)
*
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
AR088694A1
(es)
|
2011-11-17 |
2014-06-25 |
Pfizer |
Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
|
AU2015264844B2
(en)
*
|
2011-11-17 |
2016-09-01 |
Pfizer Inc. |
Cytotoxic peptides and antibody drug conjugates thereof
|
JP2014533700A
(ja)
|
2011-11-21 |
2014-12-15 |
ジェネンテック, インコーポレイテッド |
抗c−MET抗体の精製
|
CN104244718A
(zh)
*
|
2011-12-05 |
2014-12-24 |
伊格尼卡生物治疗公司 |
抗体-药物缀合物以及相关化合物、组合物和方法
|
US20150023989A1
(en)
|
2011-12-14 |
2015-01-22 |
Seattle Genetics, Inc. |
New antibody drug conjugates (adcs) and the use thereof
|
JP6242804B2
(ja)
|
2011-12-15 |
2017-12-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトcsf−1rに対する抗体及びその使用
|
EP2793940B1
(en)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013092983A2
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
KR20140116490A
(ko)
|
2012-01-18 |
2014-10-02 |
제넨테크, 인크. |
항-lrp5 항체 및 사용 방법
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
WO2013120929A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
SG11201405130UA
(en)
|
2012-02-24 |
2014-11-27 |
Stemcentrx Inc |
Anti sez6 antibodies and methods of use
|
WO2013125891A1
(ko)
|
2012-02-24 |
2013-08-29 |
(주)알테오젠 |
시스테인 잔기를 포함하는 모티프가 결합된 변형항체, 상기 변형항체를 포함하는 변형항체-약물 접합체 및 그 제조방법
|
PT2817338T
(pt)
|
2012-02-24 |
2017-11-13 |
Abbvie Stemcentrx Llc |
Moduladores de dll3 e métodos de utilização
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US20130280282A1
(en)
*
|
2012-04-24 |
2013-10-24 |
Daiichi Sankyo Co., Ltd. |
Dr5 ligand drug conjugates
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
EP2844300B1
(en)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
WO2013172961A1
(en)
*
|
2012-05-14 |
2013-11-21 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US9884127B2
(en)
|
2012-05-15 |
2018-02-06 |
Concortis Biosystems, Corp. |
Drug-conjugates, conjugation methods, and uses thereof
|
NZ630870A
(en)
*
|
2012-05-15 |
2016-10-28 |
Seattle Genetics Inc |
Self-stabilizing linker conjugates
|
US9504756B2
(en)
*
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
CN104540519B
(zh)
|
2012-05-21 |
2018-06-01 |
基因泰克公司 |
抗Ly6E抗体和免疫缀合物及使用方法
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
JP2015530867A
(ja)
|
2012-06-15 |
2015-10-29 |
ジェネンテック, インコーポレイテッド |
抗pcsk9抗体、製剤、投薬、及び使用方法
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
CN104395340B9
(zh)
|
2012-06-27 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
包含至少两个不同靶向实体的定制选择性和多特异性治疗分子的方法及其用途
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
KR20150023938A
(ko)
|
2012-07-04 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
항-테오필린 항체 및 이의 사용 방법
|
AU2013285355A1
(en)
|
2012-07-06 |
2015-01-29 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
SG11201500096YA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies
|
AU2013288931A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
MX2015000357A
(es)
|
2012-07-09 |
2015-05-12 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd22.
|
MA37840B1
(fr)
|
2012-07-09 |
2020-05-29 |
Genentech Inc |
Immunoconjugués comprenant des anticorps anti-cd79b
|
US11873281B2
(en)
*
|
2012-07-12 |
2024-01-16 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugates of cell binding molecules with cytotoxic agents
|
AU2012385228B2
(en)
|
2012-07-12 |
2016-10-06 |
Hangzhou Dac Biotech Co., Ltd |
Conjugates of cell binding molecules with cytotoxic agents
|
CN104428315B
(zh)
|
2012-07-13 |
2017-09-29 |
罗氏格黎卡特股份公司 |
双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
JP2015528818A
(ja)
|
2012-08-02 |
2015-10-01 |
ジェネンテック, インコーポレイテッド |
抗etbr抗体およびイムノコンジュゲート
|
JP2015529656A
(ja)
|
2012-08-02 |
2015-10-08 |
ジェネンテック, インコーポレイテッド |
抗etbr抗体および免疫複合体
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
UA118251C2
(uk)
*
|
2012-08-23 |
2018-12-26 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 158p1d7
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
JP2015537190A
(ja)
|
2012-09-19 |
2015-12-24 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
低減された免疫原性を有する抗体を同定するための方法
|
ES2604766T3
(es)
|
2012-09-20 |
2017-03-09 |
Celltrion, Inc. |
Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo
|
CA2879768A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
DK2906248T3
(en)
|
2012-10-12 |
2019-03-04 |
Medimmune Ltd |
Pyrrolobenzodiazepines and their conjugates
|
PT2906253T
(pt)
|
2012-10-12 |
2018-11-05 |
Medimmune Ltd |
Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
MX364328B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina.
|
EP2906249B1
(en)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
EP2906298B1
(en)
|
2012-10-12 |
2018-10-03 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
LT2906251T
(lt)
|
2012-10-12 |
2017-12-11 |
Adc Therapeutics Sa |
Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
|
NO2789793T3
(pl)
*
|
2012-10-24 |
2018-01-27 |
|
|
EP3159013A1
(en)
|
2012-10-24 |
2017-04-26 |
Polytherics Limited |
Drug-protein conjugates
|
EP2914628A1
(en)
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
TW201431880A
(zh)
|
2012-11-07 |
2014-08-16 |
Pfizer |
抗切口3(anti-notch3)抗體及抗體-藥物共軛體
|
PE20150956A1
(es)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
|
US10036010B2
(en)
|
2012-11-09 |
2018-07-31 |
Innate Pharma |
Recognition tags for TGase-mediated conjugation
|
CN104968367B
(zh)
|
2012-11-13 |
2018-04-13 |
弗·哈夫曼-拉罗切有限公司 |
抗血凝素抗体和使用方法
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
JP6334553B2
(ja)
|
2012-12-10 |
2018-05-30 |
メルサナ セラピューティクス,インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
WO2014100740A1
(en)
|
2012-12-21 |
2014-06-26 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
TWI716339B
(zh)
|
2012-12-21 |
2021-01-21 |
荷蘭商台醫(有限合夥)公司 |
親水性自消耗連接子及彼等之共軛物
|
EP2927227A4
(en)
*
|
2013-01-03 |
2015-12-30 |
Celltrion Inc |
ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
JP6377635B2
(ja)
|
2013-01-10 |
2018-08-22 |
ゲンマブ ビー.ブイ. |
ヒトIgG1Fc領域変異体およびその使用
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
RU2519546C1
(ru)
|
2013-01-16 |
2014-06-10 |
Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") |
КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
|
CN103933575B
(zh)
*
|
2013-01-23 |
2017-09-29 |
上海新理念生物医药科技有限公司 |
一种三齿型连接子及其应用
|
US10029017B2
(en)
|
2013-01-29 |
2018-07-24 |
The Regents Of The University Of California |
Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
|
WO2014120974A1
(en)
|
2013-01-30 |
2014-08-07 |
Avelas Biosciences, Inc. |
Selective delivery molecules and methods of use
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
US9968687B2
(en)
|
2013-02-22 |
2018-05-15 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibody drug conjugates
|
WO2014131715A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
EP2983701A2
(en)
|
2013-03-11 |
2016-02-17 |
Genzyme Corporation |
Site-specific antibody-drug conjugation through glycoengineering
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
SG11201507037XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Anti-b7-h4 antibodies and immunoconjugates
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
BR112015023084A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
|
KR20230070054A
(ko)
|
2013-03-15 |
2023-05-19 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
CN105121470A
(zh)
|
2013-03-15 |
2015-12-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
ES2699599T3
(es)
|
2013-03-15 |
2019-02-11 |
Abbvie Biotherapeutics Inc |
Variantes de Fc
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
ES2727134T3
(es)
|
2013-03-15 |
2019-10-14 |
Abbvie Deutschland |
Formulaciones de conjugado de fármaco y anticuerpo anti-EGFR
|
KR102561553B1
(ko)
|
2013-03-15 |
2023-07-31 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
TW201522374A
(zh)
|
2013-03-15 |
2015-06-16 |
Genentech Inc |
抗crth2抗體及使用方法
|
JP2016520528A
(ja)
|
2013-03-15 |
2016-07-14 |
ジェネンテック, インコーポレイテッド |
癌の治療及び抗癌剤耐性の防止方法
|
AU2014240012A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Inc. |
Antibody drug conjugate (ADC) purification
|
EP2976362B1
(en)
|
2013-03-19 |
2019-10-23 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
TWI692483B
(zh)
*
|
2013-05-31 |
2020-05-01 |
美商建南德克公司 |
抗壁磷壁酸抗體(anti-wall teichoic acid antibodies)及結合物
|
EP3004161B1
(en)
|
2013-05-31 |
2019-10-02 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
US9803002B2
(en)
*
|
2013-05-31 |
2017-10-31 |
Genentench, Inc. |
Anti-wall teichoic antibodies and conjugates
|
LT3004162T
(lt)
*
|
2013-05-31 |
2020-06-10 |
Genentech, Inc. |
Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
JP6824735B2
(ja)
|
2013-06-06 |
2021-02-03 |
ピエール、ファーブル、メディカマン |
抗C10orf54抗体およびその使用方法
|
WO2014197866A1
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Modified antibodies and related compounds, compositions, and methods of use
|
WO2014197854A1
(en)
*
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
AR096687A1
(es)
|
2013-06-24 |
2016-01-27 |
Genentech Inc |
Anticuerpos anti-fcrh5
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
JP6510518B2
(ja)
|
2013-08-01 |
2019-05-08 |
アジェンシス,インコーポレイテッド |
Cd37タンパク質に結合する抗体薬物結合体(adc)
|
SG11201601005XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CA3090644C
(en)
|
2013-08-26 |
2023-02-07 |
Biontech Research And Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
US9993566B2
(en)
|
2013-08-28 |
2018-06-12 |
Abbvie Stemcentrx Llc |
SEZ6 modulators and methods of use
|
JP2016531915A
(ja)
|
2013-08-28 |
2016-10-13 |
ステムセントリックス, インコーポレイテッド |
部位特異的抗体コンジュゲーション方法および組成物
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
EP3041484B1
(en)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
JP6282745B2
(ja)
|
2013-09-12 |
2018-02-21 |
ハロザイム インコーポレイテッド |
修飾抗上皮成長因子受容体抗体およびその使用法
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
WO2015042108A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CN115068626A
(zh)
|
2013-10-11 |
2022-09-20 |
阿萨纳生物科技有限责任公司 |
蛋白-聚合物-药物缀合物
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054991B1
(en)
|
2013-10-11 |
2019-04-03 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
MX365742B
(es)
|
2013-10-11 |
2019-06-12 |
Oxford Biotherapeutics Ltd |
Anticuerpos conjugados contra ly75 para el tratamiento del cancer.
|
RU2016134258A
(ru)
|
2013-10-15 |
2018-02-28 |
Сорренто Терапьютикс Инк. |
Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
|
EA201690780A1
(ru)
|
2013-10-15 |
2016-08-31 |
Сиэтл Дженетикс, Инк. |
Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
|
US9644037B2
(en)
|
2013-10-18 |
2017-05-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
|
MX2016004802A
(es)
|
2013-10-18 |
2016-07-18 |
Genentech Inc |
Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
|
AR098126A1
(es)
|
2013-10-21 |
2016-05-04 |
Genentech Inc |
Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
AU2014353150A1
(en)
|
2013-11-19 |
2016-07-07 |
Vanderbilt University |
Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
|
KR102372245B1
(ko)
|
2013-11-21 |
2022-03-08 |
젠맵 에이/에스 |
항체-약물 접합체 동결건조 제제
|
US10457976B2
(en)
|
2013-11-25 |
2019-10-29 |
Seattle Genetics, Inc. |
Preparing antibodies from CHO cell cultures for conjugation
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
CN103665104B
(zh)
*
|
2013-12-09 |
2015-05-20 |
天津市康信医药科技有限公司 |
一种mmaf中间体五肽的合成方法
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
WO2015095212A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CN105873614B
(zh)
|
2013-12-16 |
2020-10-30 |
基因泰克公司 |
肽模拟化合物及其抗体-药物缀合物
|
EP3753578A1
(en)
|
2013-12-17 |
2020-12-23 |
Novartis AG |
Cytotoxic peptides and conjugates thereof
|
PL3083689T3
(pl)
|
2013-12-17 |
2020-10-19 |
Genentech, Inc. |
Przeciwciała anty-CD3 i sposoby ich zastosowania
|
TWI777502B
(zh)
|
2013-12-19 |
2022-09-11 |
美商西雅圖遺傳學公司 |
與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
NZ720736A
(en)
|
2013-12-23 |
2020-08-28 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
|
US10675355B2
(en)
|
2013-12-27 |
2020-06-09 |
Var2 Pharmaceuticals Aps |
VAR2CSA-drug conjugates
|
AU2014373574B2
(en)
*
|
2013-12-27 |
2020-07-16 |
Zymeworks Bc Inc. |
Sulfonamide-containing linkage systems for drug conjugates
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
KR102278429B1
(ko)
|
2014-01-03 |
2021-07-16 |
에프. 호프만-라 로슈 아게 |
공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
CN104861063A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
靶向her2阳性肿瘤的化合物和组合物
|
CN104861067A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
AU2015205753A1
(en)
|
2014-01-10 |
2016-07-21 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating HER2 positive tumors
|
CN104861064A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
靶向表达egfr的肿瘤的化合物和组合物
|
EP3094350B1
(en)
|
2014-01-15 |
2020-03-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Cartilage targeting agents and their use
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
SG11201605903SA
(en)
|
2014-01-24 |
2016-08-30 |
Genentech Inc |
Methods of using anti-steap1 antibodies and immunoconjugates
|
CA2937561A1
(en)
*
|
2014-01-29 |
2015-08-06 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
|
CA2938450C
(en)
|
2014-02-11 |
2023-10-17 |
Seattle Genetics, Inc. |
Selective reduction of proteins
|
RS57608B1
(sr)
|
2014-02-12 |
2018-11-30 |
Hoffmann La Roche |
Anti-jagged1 antitela i načini primene
|
ES2885686T3
(es)
|
2014-02-17 |
2021-12-15 |
Seagen Inc |
Conjugados anticuerpo-fármaco hidrófilos
|
KR20160124165A
(ko)
|
2014-02-21 |
2016-10-26 |
제넨테크, 인크. |
항-il-13/il-17 이중특이적 항체 및 그의 용도
|
CN106550593A
(zh)
|
2014-02-21 |
2017-03-29 |
艾伯维施特姆森特克斯有限责任公司 |
用于黑素瘤的抗‑dll3抗体和药物缀合物
|
FI3122757T3
(fi)
|
2014-02-28 |
2023-10-10 |
Hangzhou Dac Biotech Co Ltd |
Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
|
HRP20211748T1
(hr)
|
2014-03-14 |
2022-02-18 |
F. Hoffmann - La Roche Ag |
Postupci i sastavi za sekreciju heterolognih polipeptida
|
SG11201607198WA
(en)
|
2014-03-19 |
2016-09-29 |
Genzyme Corp |
Site-specific glycoengineering of targeting moieties
|
MX371403B
(es)
|
2014-03-20 |
2020-01-29 |
Bristol Myers Squibb Co |
Moleculas de andamiaje a base de fibronectina estabilizada.
|
US9533982B2
(en)
|
2014-03-20 |
2017-01-03 |
Vanderbilt University |
Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
|
CN110845615B
(zh)
|
2014-03-21 |
2023-10-20 |
艾伯维公司 |
抗-egfr抗体及抗体药物偶联物
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
RS59907B1
(sr)
|
2014-03-28 |
2020-03-31 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
US9260478B2
(en)
|
2014-04-04 |
2016-02-16 |
Shanghui Hu |
Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
|
KR20160141727A
(ko)
*
|
2014-04-08 |
2016-12-09 |
시애틀 지네틱스, 인크. |
Cd19-항체 약물 컨쥬게이트의 최적의 주입
|
WO2015165413A1
(zh)
|
2014-04-29 |
2015-11-05 |
秦刚 |
一种新型的稳定型抗体药物耦联物及其制备方法和用途
|
BR122021009041B1
(pt)
|
2014-05-06 |
2022-11-29 |
Genentech, Inc |
Métodos para a preparação de uma proteína heteromultimérica
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
KR20170005142A
(ko)
|
2014-05-27 |
2017-01-11 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
EP3149037A4
(en)
|
2014-05-27 |
2018-01-10 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
US9856324B2
(en)
|
2014-06-04 |
2018-01-02 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
CN106604741B
(zh)
|
2014-06-12 |
2021-06-11 |
石药集团德丰有限公司 |
酶法制备同质的抗体-药物缀合物
|
EP3154544B1
(en)
|
2014-06-12 |
2023-08-02 |
Cedars-Sinai Medical Center |
Compositions and methods for treating cancers
|
WO2015189791A1
(en)
|
2014-06-13 |
2015-12-17 |
Novartis Ag |
Auristatin derivatives and conjugates thereof
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
MX2016017117A
(es)
*
|
2014-06-20 |
2018-01-12 |
Abgenomics Int Inc |
Conjugados de anticuerpo her2-farmaco.
|
AU2015276821A1
(en)
|
2014-06-20 |
2017-01-12 |
Abgenomics International Inc. |
Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
|
CA2947504A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
US10973920B2
(en)
|
2014-06-30 |
2021-04-13 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
DK3166976T3
(da)
|
2014-07-09 |
2022-04-11 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1-kombinationer til behandling af tumorer
|
BR112017000316A2
(pt)
|
2014-07-11 |
2017-10-31 |
Genmab As |
?anticorpo, imunoconjugado, composição, construção de ácido nucleico, vetor de expressão, hibridoma, métodos para tratamento de câncer, para diagnosticar uma doença, inibir crescimento e/ou proliferação de um tumor de célula e produzir um anticorpo, uso, e, kit?
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
WO2016008112A1
(en)
*
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
US20160060360A1
(en)
|
2014-07-24 |
2016-03-03 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10934360B2
(en)
|
2014-07-31 |
2021-03-02 |
The Hong Kong University Of Science And Technology |
Human monoclonal antibodies against EPHA4 and their use
|
EP3186284B1
(en)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
CN112546238A
(zh)
*
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
CN113827737A
(zh)
|
2014-09-11 |
2021-12-24 |
西雅图基因公司 |
含叔胺药物物质的靶向递送
|
SG10201809668TA
(en)
|
2014-09-12 |
2018-11-29 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
KR102494557B1
(ko)
|
2014-09-17 |
2023-02-02 |
자임워크스 비씨 인코포레이티드 |
세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
|
RU2727663C2
(ru)
|
2014-09-17 |
2020-07-22 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
US9550778B2
(en)
|
2014-10-03 |
2017-01-24 |
Vanderbilt University |
Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
|
US10064952B2
(en)
|
2014-10-09 |
2018-09-04 |
Genzyme Corporation |
Glycoengineered antibody drug conjugates
|
CN107106685A
(zh)
*
|
2014-10-10 |
2017-08-29 |
辉瑞公司 |
协同澳瑞他汀组合
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
GB201418809D0
(en)
|
2014-10-22 |
2014-12-03 |
Univ Swansea |
Therapeutic agents and uses thereof
|
WO2016063006A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Polytherics Limited |
Conjugates and conjugating reagents
|
GB201419108D0
(en)
*
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
CN107148283A
(zh)
|
2014-10-31 |
2017-09-08 |
豪夫迈·罗氏有限公司 |
抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
MX2017005148A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
|
US10093730B2
(en)
|
2014-11-10 |
2018-10-09 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
PL3221349T3
(pl)
|
2014-11-19 |
2021-05-17 |
Axon Neuroscience Se |
Humanizowane przeciwciała tau w chorobie Alzheimera
|
HUE050596T2
(hu)
|
2014-11-21 |
2020-12-28 |
Bristol Myers Squibb Co |
Antitestek CD73 ellen és azok felhasználásai
|
MX2017006323A
(es)
|
2014-11-21 |
2017-08-21 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
CA2969067A1
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Novel pd-l1 binding polypeptides for imaging
|
MX2017006770A
(es)
|
2014-11-25 |
2018-02-09 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepina y anticuerpo.
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
EP3226908A1
(en)
*
|
2014-12-03 |
2017-10-11 |
F.Hoffmann-La Roche Ag |
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
|
JP6742314B2
(ja)
*
|
2014-12-03 |
2020-08-19 |
ジェネンテック, インコーポレイテッド |
抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用
|
AU2015358367B2
(en)
|
2014-12-04 |
2020-07-02 |
Celgene Corporation |
Biomolecule conjugates
|
SI3227336T1
(sl)
|
2014-12-05 |
2019-10-30 |
Hoffmann La Roche |
Protitelesa proti CD79b in postopki uporabe
|
CA2970161A1
(en)
*
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Bcl-xl inhibitory compounds and antibody drug conjugates including the same
|
US20160339117A1
(en)
*
|
2014-12-09 |
2016-11-24 |
Abbvie Inc. |
BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
|
EP3229844B1
(en)
*
|
2014-12-09 |
2020-03-04 |
AbbVie Inc. |
Antibody drug conjugates with cell permeable bcl-xl inhibitors
|
WO2016091891A1
(en)
|
2014-12-09 |
2016-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against axl
|
JP2018502840A
(ja)
|
2014-12-10 |
2018-02-01 |
ジェネンテック, インコーポレイテッド |
血液脳関門受容体抗体及び使用方法
|
EP3233127A1
(de)
|
2014-12-15 |
2017-10-25 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
|
TW201809008A
(zh)
|
2014-12-19 |
2018-03-16 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AR103442A1
(es)
|
2015-01-16 |
2017-05-10 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos de ror1
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
WO2016118191A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CN107849090A
(zh)
*
|
2015-01-28 |
2018-03-27 |
索伦托医疗有限公司 |
抗体药物偶联物
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
RU2708461C2
(ru)
*
|
2015-02-15 |
2019-12-09 |
Цзянсу Хэнжуй Медсин Ко., Лтд. |
Конъюгат лиганда с цитотоксическим лекарственным средством, способ его получения и применение
|
EP3261665A1
(en)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
US10472395B2
(en)
|
2015-03-05 |
2019-11-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
AU2016229143B2
(en)
|
2015-03-09 |
2022-01-13 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to FLT3 proteins
|
EP3268048B1
(en)
|
2015-03-10 |
2019-05-08 |
Bristol-Myers Squibb Company |
Antibodies conjugatable by transglutaminase and conjugates made therefrom
|
BR112017019617A2
(pt)
|
2015-03-18 |
2018-05-22 |
Seattle Genetics, Inc. |
Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
|
KR20170128567A
(ko)
|
2015-03-23 |
2017-11-22 |
바이엘 파마 악티엔게젤샤프트 |
항-ceacam6 항체 및 그의 용도
|
GB201505585D0
(en)
*
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
JP6869187B2
(ja)
|
2015-04-07 |
2021-05-12 |
メモリアル スローン ケタリング キャンサー センター |
ナノ粒子イムノコンジュゲート
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
WO2016165580A1
(zh)
*
|
2015-04-17 |
2016-10-20 |
江苏恒瑞医药股份有限公司 |
抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
|
CN106188293A
(zh)
*
|
2015-04-17 |
2016-12-07 |
江苏恒瑞医药股份有限公司 |
抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
EP3286227A2
(en)
|
2015-04-24 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Multispecific antigen-binding proteins
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN104910277B
(zh)
*
|
2015-05-19 |
2016-02-24 |
北京东方百泰生物科技有限公司 |
新型人源化抗cd22抗体-单甲基阿里他汀e偶联物及其制备方法
|
US10596259B2
(en)
|
2015-05-20 |
2020-03-24 |
The Regents Of The University Of California |
Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
CN106267225B
(zh)
*
|
2015-05-29 |
2020-03-06 |
上海新理念生物医药科技有限公司 |
三马来酰亚胺型连接子及其应用
|
LT3303396T
(lt)
|
2015-05-29 |
2023-01-10 |
Bristol-Myers Squibb Company |
Antikūnai prieš ox40 ir jų panaudojimo būdai
|
WO2016196298A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Therapeutic and diagnolstic methods for cancer
|
CN106279352B
(zh)
|
2015-05-29 |
2020-05-22 |
上海新理念生物医药科技有限公司 |
海兔毒素10的衍生物及其应用
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
CN106267226A
(zh)
*
|
2015-06-09 |
2017-01-04 |
北京和理咨询有限公司 |
治疗骨肉瘤的雷公藤甲素衍生物及其制备方法
|
ES2961346T3
(es)
|
2015-06-12 |
2024-03-11 |
Lentigen Tech Inc |
Procedimiento para tratar cáncer con células T modificadas genéticamente
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
EP4299073A3
(en)
|
2015-06-16 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体及び使用方法
|
WO2016205531A2
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
CN107921144B
(zh)
*
|
2015-06-20 |
2023-11-28 |
杭州多禧生物科技有限公司 |
澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
|
EP3310440A1
(de)
|
2015-06-22 |
2018-04-25 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
|
CN108025086A
(zh)
|
2015-06-23 |
2018-05-11 |
拜耳制药股份公司 |
Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc)
|
EP4074730A1
(en)
|
2015-06-24 |
2022-10-19 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies with tailored affinity
|
EP3313885A1
(en)
|
2015-06-29 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody for use in organ transplantation
|
PL3316909T3
(pl)
|
2015-06-30 |
2023-11-20 |
Seagen Inc. |
Przeciwciała anty-ntb-a i powiązane kompozycje i sposoby
|
JP6892431B2
(ja)
|
2015-07-10 |
2021-06-23 |
ゲンマブ エー/エス |
癌治療用のaxl特異的抗体−薬物コンジュゲート
|
WO2015151081A2
(en)
|
2015-07-12 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
WO2017019489A1
(en)
|
2015-07-24 |
2017-02-02 |
George Robert Pettit |
Quinstatin compounds
|
CN111533778B
(zh)
*
|
2015-07-28 |
2023-04-25 |
上海皓元生物医药科技有限公司 |
一种抗体偶联药物连接子的工业化生产方法
|
US10669343B2
(en)
|
2015-08-05 |
2020-06-02 |
Janssen Biotech, Inc. |
Anti-CD154 antibodies and methods of using them
|
EP4137158A1
(en)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CA2998740A1
(en)
*
|
2015-09-17 |
2017-03-23 |
The Scripps Research Institute |
Dual variable domain immunoconjugates and uses thereof
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
US10584160B2
(en)
|
2015-09-23 |
2020-03-10 |
Bristol-Myers Squibb Company |
Glypican-3-binding fibronectin based scaffold molecules
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
EP3355921A4
(en)
|
2015-09-30 |
2019-05-22 |
Janssen Biotech, Inc. |
ANTAGONIST ANTIBODIES SPECIFICALLY BINDING TO HUMAN CD40 AND METHODS OF USE
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Antibodies against pd1 and methods of their use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
SG10202008325XA
(en)
|
2015-10-02 |
2020-09-29 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
WO2017058808A1
(en)
|
2015-10-02 |
2017-04-06 |
Sirenas Llc |
Anti-cancer compounds and conjugates thereof
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
CN108779162B
(zh)
|
2015-10-09 |
2021-12-07 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
ES2904553T3
(es)
|
2015-10-30 |
2022-04-05 |
Hoffmann La Roche |
Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
JP6486316B2
(ja)
*
|
2015-11-03 |
2019-03-20 |
財團法人工業技術研究院Industrial Technology Research Institute |
抗体−薬物複合体(adc)およびそれを形成するための方法
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
AU2016359230B2
(en)
|
2015-11-25 |
2020-04-23 |
Legochem Biosciences, Inc. |
Conjugates comprising self-immolative groups and methods related thereto
|
CA3006247A1
(en)
|
2015-11-25 |
2017-06-01 |
Legochem Biosciences, Inc. |
Conjugates comprising peptide groups and methods related thereto
|
CN113599533A
(zh)
|
2015-11-25 |
2021-11-05 |
乐高化学生物科学股份有限公司 |
包含分支接头的抗体-药物缀合物及其相关方法
|
TWI727380B
(zh)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
WO2017095805A1
(en)
*
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
TWI814699B
(zh)
|
2015-12-04 |
2023-09-11 |
美商思進公司 |
四級胺化妥布賴森(tubulysin)化合物之結合物
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
SG11201610782YA
(en)
|
2015-12-18 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
BR112018012524A2
(pt)
|
2015-12-21 |
2018-12-11 |
Bristol Myers Squibb Co |
anticorpos variantes para conjugação sítio-específica
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
TWI753875B
(zh)
|
2016-01-08 |
2022-02-01 |
美商美國全心醫藥生技股份有限公司 |
四價抗psgl-1抗體及其用途
|
US20190030180A1
(en)
|
2016-01-13 |
2019-01-31 |
Genmab A/S |
Formulation for antibody and drug conjugate thereof
|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
CA3011455A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CN107029244B
(zh)
*
|
2016-02-04 |
2021-04-27 |
浙江昭华生物医药有限公司 |
抗her2抗体-药物偶联物及其应用
|
US20170233484A1
(en)
|
2016-02-17 |
2017-08-17 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
AU2017223532A1
(en)
|
2016-02-26 |
2018-08-30 |
Jiangsu Hengrui Medicine Co., Ltd. |
New toxin and method for preparing intermediate thereof
|
EP3419655A1
(en)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US20190060473A1
(en)
|
2016-02-29 |
2019-02-28 |
Madrigal Pharmaceuticals, Inc. |
Hsp90 inhibitor drug conjugates
|
US11098052B2
(en)
|
2016-03-02 |
2021-08-24 |
Arizona Board Of Regents On Behalf Of Arizona State University |
4-azapodophylotoxins compounds
|
CN108713020A
(zh)
|
2016-03-04 |
2018-10-26 |
豪夫迈·罗氏有限公司 |
制备抗体-利福霉素缀合物的方法
|
BR112018067368A2
(pt)
|
2016-03-04 |
2019-01-15 |
Bristol-Myers Squibb Company |
terapia de combinação com anticorpos anti-cd73
|
US10336784B2
(en)
|
2016-03-08 |
2019-07-02 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
CA3016474A1
(en)
|
2016-03-15 |
2017-09-21 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
KR102438140B1
(ko)
|
2016-03-22 |
2022-08-31 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
인간화 항-클라우딘-1 항체 및 이의 용도
|
RU2018136778A
(ru)
|
2016-03-24 |
2020-04-24 |
Байер Фарма Акциенгезельшафт |
Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы
|
WO2017165851A1
(en)
|
2016-03-25 |
2017-09-28 |
Seattle Genetics, Inc. |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
CN109219610A
(zh)
*
|
2016-04-04 |
2019-01-15 |
新泽西州立拉特格斯大学 |
拓扑异构酶毒物
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
BR112018071105A2
(pt)
|
2016-04-15 |
2019-02-26 |
Macrogenics, Inc. |
conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso
|
JP6735355B2
(ja)
|
2016-04-15 |
2020-08-05 |
バイオアトラ、エルエルシー |
抗Axl抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CN109071634A
(zh)
|
2016-04-26 |
2018-12-21 |
R.P.谢勒技术有限责任公司 |
抗体偶联物及其制备和使用方法
|
CN109071635B
(zh)
|
2016-05-02 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Contorsbody-单链靶标结合物
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
IL294146B2
(en)
*
|
2016-05-17 |
2024-01-01 |
Abbvie Biotherapeutics Inc |
Antibody conjugates against cMet with a drug and methods of using them
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
WO2018220099A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3464400B1
(en)
|
2016-06-03 |
2022-04-06 |
Novacyte Therapeutics Company.,LTD |
Polymer linkers and their uses
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
BR112018075644A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de anticorpo e fármaco
|
MX2018015274A
(es)
|
2016-06-08 |
2019-10-07 |
Abbvie Inc |
Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
|
TW202304996A
(zh)
|
2016-06-08 |
2023-02-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
US20200002421A1
(en)
|
2016-06-08 |
2020-01-02 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
EP3469000A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
RU2767357C2
(ru)
|
2016-06-14 |
2022-03-17 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
WO2017216028A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
CN108472371B
(zh)
*
|
2016-07-05 |
2022-05-24 |
江苏恒瑞医药股份有限公司 |
Egfr抗体-药物偶联物及其在医药上的应用
|
MA45784A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
|
WO2018025982A1
(ja)
|
2016-08-05 |
2018-02-08 |
中外製薬株式会社 |
Il-8関連疾患の治療用又は予防用組成物
|
SG11201900699QA
(en)
|
2016-08-09 |
2019-02-27 |
Seattle Genetics Inc |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
CN106674347B
(zh)
*
|
2016-08-16 |
2019-12-13 |
滨州医学院 |
一种新型耳抑素抗体
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018045325A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
JP6453826B2
(ja)
*
|
2016-09-28 |
2019-01-16 |
トヨタ自動車株式会社 |
摺動部材およびその製造方法
|
US10517958B2
(en)
|
2016-10-04 |
2019-12-31 |
Zymeworks Inc. |
Compositions and methods for the treatment of platinum-drug resistant cancer
|
WO2018065501A1
(en)
|
2016-10-05 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Methods for preparing antibody drug conjugates
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
EP3526240A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
US11638762B2
(en)
|
2016-10-18 |
2023-05-02 |
Seagen Inc. |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
CN110177805B
(zh)
|
2016-10-19 |
2024-04-02 |
英温拉公司 |
抗体构建体
|
EP3532502A1
(en)
|
2016-10-25 |
2019-09-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the cd160 transmembrane isoform
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
BR112019008702A2
(pt)
|
2016-11-01 |
2019-07-16 |
Genmab B.V. |
polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
|
SG10202104259RA
(en)
|
2016-11-08 |
2021-06-29 |
Regeneron Pharma |
Steroids and protein-conjugates thereof
|
KR102459468B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
CA3042889A1
(en)
*
|
2016-11-14 |
2018-05-17 |
Millennium Pharmaceuticals, Inc. |
Non-adult human dosing of anti-cd30 antibody-drug conjugates
|
TWI791471B
(zh)
|
2016-11-15 |
2023-02-11 |
美商建南德克公司 |
用於用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
CN110023334B
(zh)
|
2016-11-21 |
2023-11-14 |
科雅博有限责任公司 |
抗gp73抗体和免疫偶联物
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
US10864279B2
(en)
|
2016-12-16 |
2020-12-15 |
Industrial Technology Research Institute |
Linker-drug and antibody-drug conjugate (ADC) employing the same
|
CN110312533B
(zh)
|
2016-12-21 |
2023-11-03 |
拜耳公司 |
具有酶促可裂解的基团的细胞毒性活性剂的前药
|
JP7066714B2
(ja)
|
2016-12-21 |
2022-05-13 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc)
|
US11433140B2
(en)
|
2016-12-21 |
2022-09-06 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (ADCs) having KSP inhibitors
|
CN110072553B
(zh)
|
2016-12-22 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
|
WO2018115485A1
(en)
|
2016-12-22 |
2018-06-28 |
Pierfrancesco Tassone |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
WO2018129384A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
CA3049252C
(en)
|
2017-01-09 |
2020-11-24 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
EP3574016A2
(en)
|
2017-01-24 |
2019-12-04 |
Innate Pharma |
NKp46 BINDING AGENTS
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
ES2871001T3
(es)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110494453B
(zh)
|
2017-02-10 |
2023-05-26 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
JP7341060B2
(ja)
|
2017-02-10 |
2023-09-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
|
AU2018220516A1
(en)
|
2017-02-16 |
2019-09-19 |
Sonnet BioTherapeutics, Inc. |
Albumin binding domain fusion proteins
|
CN108452318B
(zh)
*
|
2017-02-17 |
2023-05-26 |
浙江特瑞思药业股份有限公司 |
靶向cd20的抗体偶联药物及其制备方法和用途
|
CN108452319A
(zh)
*
|
2017-02-20 |
2018-08-28 |
浙江特瑞思药业股份有限公司 |
靶向cd20的抗体偶联药物制剂
|
CN110352074A
(zh)
|
2017-02-28 |
2019-10-18 |
西雅图遗传学公司 |
用于偶联的半胱氨酸突变抗体
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
WO2018163131A1
(en)
|
2017-03-10 |
2018-09-13 |
Quiapeg Pharmaceuticals Ab |
Releasable conjugates
|
IL269398B1
(en)
|
2017-03-24 |
2024-01-01 |
Seagen Inc |
A process for the preparation of glucuronide-drug binders and their intermediates
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
KR101938800B1
(ko)
|
2017-03-29 |
2019-04-10 |
주식회사 레고켐 바이오사이언스 |
피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
JP7284707B2
(ja)
|
2017-04-07 |
2023-05-31 |
ジュノー セラピューティクス インコーポレイテッド |
前立腺特異的膜抗原(psma)またはその改変型を発現する操作された細胞および関連方法
|
PT3612537T
(pt)
|
2017-04-18 |
2022-08-29 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
CN110312730A
(zh)
*
|
2017-04-19 |
2019-10-08 |
四川科伦博泰生物医药股份有限公司 |
细胞毒素和偶联物、 其用途和制备方法
|
EP3612567A4
(en)
|
2017-04-19 |
2020-11-11 |
Bluefin Biomedicine, Inc. |
ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
|
JP7408396B2
(ja)
|
2017-04-20 |
2024-01-05 |
アーデーセー セラピューティクス ソシエテ アノニム |
併用療法
|
CA3060206A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
EP3615572A1
(en)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AU2018259856A1
(en)
|
2017-04-28 |
2019-11-14 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
US11666657B2
(en)
|
2017-05-16 |
2023-06-06 |
Universite De Strasbourg |
Protein-drug conjugates and their use in the treatment of cancers
|
US11491237B2
(en)
|
2017-05-18 |
2022-11-08 |
Regeneron Pharmaceuticals, Inc. |
Cyclodextrin protein drug conjugates
|
JP2020521751A
(ja)
|
2017-05-25 |
2020-07-27 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
修飾重鎖定常領域を含む抗体
|
WO2018229222A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd19 adc
|
EP3641802A1
(en)
|
2017-06-22 |
2020-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
WO2018237262A1
(en)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
METHODS FOR PRODUCING POLYMERIC MATRICES TRANSPORTING MEDICAMENTS, AND PROTEIN-POLYMER-MEDICINE CONJUGATES
|
TWI804499B
(zh)
|
2017-06-23 |
2023-06-11 |
美商維洛斯生物公司 |
Ror1抗體免疫接合物
|
EP3641771A4
(en)
|
2017-06-23 |
2020-12-16 |
Birdie Biopharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
CN111132733A
(zh)
|
2017-06-30 |
2020-05-08 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
|
CN107375941A
(zh)
*
|
2017-07-17 |
2017-11-24 |
中国药科大学 |
一种抗人dll4单克隆抗体与海兔毒素衍生物mmae的偶联物
|
CN107296961A
(zh)
*
|
2017-07-17 |
2017-10-27 |
中国药科大学 |
一种抗人dll4单克隆抗体与阿霉素的偶联物
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
US10442867B2
(en)
|
2017-07-31 |
2019-10-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
CN107652219B
(zh)
|
2017-08-14 |
2021-06-08 |
上海新理念生物医药科技有限公司 |
四马来酰亚胺型连接子及其应用
|
MY194477A
(en)
|
2017-08-18 |
2022-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
KR20200044016A
(ko)
|
2017-08-24 |
2020-04-28 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 그 용도
|
WO2019055842A1
(en)
|
2017-09-15 |
2019-03-21 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD19 IMMUNOTHERAPY
|
EP3684814A1
(en)
|
2017-09-18 |
2020-07-29 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
IL273252B2
(en)
|
2017-09-20 |
2024-03-01 |
Mersana Therapeutics Inc |
Preparations and methods for predicting response to NAPI2B-targeted therapy
|
BR112020004307A2
(pt)
|
2017-09-20 |
2020-11-10 |
Ph Pharma Co., Ltd. |
análogos de tailanestatina
|
CN107583058B
(zh)
*
|
2017-09-20 |
2020-09-18 |
厉保秋 |
一种t-2毒素-抗体缀合物及其用途
|
WO2019071028A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
US11332527B2
(en)
|
2017-10-12 |
2022-05-17 |
Keio University |
Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
ES2958849T3
(es)
|
2017-10-16 |
2024-02-15 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia anti-CD22
|
US20210190764A1
(en)
|
2017-10-20 |
2021-06-24 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring cellular uptake of molecules
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
BR112020008323A2
(pt)
|
2017-11-01 |
2020-11-03 |
Juno Therapeutics Inc |
anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
PL3704146T3
(pl)
|
2017-11-01 |
2022-03-07 |
F. Hoffmann-La Roche Ag |
Przeciwciało Contorsbody trifab
|
CN107789631B
(zh)
*
|
2017-11-03 |
2021-03-16 |
合肥瀚科迈博生物技术有限公司 |
抗人ErbB2双表位抗体-药物偶联物及其应用
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|
CN111566081B
(zh)
*
|
2017-11-20 |
2021-04-06 |
天津安百胜医疗科技有限公司 |
一种双酰胺复合物及其制备方法和用途
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
WO2019105972A1
(en)
|
2017-11-30 |
2019-06-06 |
Bayer Aktiengesellschaft |
Ildr2 antagonists and combinations thereof
|
AU2018375412A1
(en)
|
2017-11-30 |
2020-05-28 |
Seagen Inc. |
Process for the preparation of drug linker compounds
|
MX2020005640A
(es)
|
2017-12-01 |
2020-08-20 |
Seattle Genetics Inc |
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
|
AU2018375375A1
(en)
|
2017-12-01 |
2020-05-28 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
MA51103A
(fr)
|
2017-12-06 |
2020-10-14 |
Avidity Biosciences Inc |
Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
WO2019126464A2
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
CN110090308B
(zh)
*
|
2018-01-30 |
2023-03-24 |
四川科伦博泰生物医药股份有限公司 |
制备偶联物的方法
|
AU2019218959A1
(en)
|
2018-02-08 |
2020-09-03 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
EP3755707A1
(en)
|
2018-02-20 |
2020-12-30 |
Seagen Inc. |
Hydrophobic auristatin f compounds and conjugates thereof
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
CN111629759A
(zh)
|
2018-03-09 |
2020-09-04 |
奎亚培格制药公司 |
可释放的抗体结合物
|
MX2020009469A
(es)
|
2018-03-13 |
2021-01-29 |
Zymeworks Inc |
Conjugados de anticuerpo y farmaco anti-her2 biparatopicos y metodos de uso.
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
KR20200135841A
(ko)
|
2018-03-23 |
2020-12-03 |
시애틀 지네틱스, 인크. |
고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
|
WO2019186276A2
(en)
|
2018-03-28 |
2019-10-03 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
MX2020010729A
(es)
|
2018-04-13 |
2021-03-09 |
Genentech Inc |
Formulaciones de inmunoconjugado anti-cd79b estables.
|
WO2019204364A1
(en)
*
|
2018-04-16 |
2019-10-24 |
Avelas Biosciences, Inc. |
Compositions and methods for the selective delivery of therapeutic and imaging agents
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
WO2019212356A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
EP3790584A4
(en)
|
2018-05-07 |
2022-03-30 |
Genmab A/S |
METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DUG CONJUGATE
|
EP3790899A1
(en)
|
2018-05-09 |
2021-03-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-msr1 antibodies and methods of use thereof
|
WO2019215510A2
(en)
|
2018-05-09 |
2019-11-14 |
Legochem Biosciences, Inc. |
Compositions and methods related to anti-cd19 antibody drug conjugates
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
CA3100007A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
CN110507824A
(zh)
*
|
2018-05-21 |
2019-11-29 |
荣昌生物制药(烟台)有限公司 |
一种抗间皮素抗体及其抗体药物缀合物
|
WO2019224718A2
(en)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
EP3802580A1
(en)
|
2018-06-05 |
2021-04-14 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
EP3811978A4
(en)
|
2018-06-14 |
2022-03-16 |
Ajinomoto Co., Inc. |
SUBSTANCE HAVING AFFINITY FOR AN ANTIBODY, AND COMPOUND OR SALT THEREOF HAVING A BIOORTHOGONAL FUNCTIONAL GROUP
|
CN112262152A
(zh)
|
2018-06-14 |
2021-01-22 |
味之素株式会社 |
具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
EP3806905A4
(en)
*
|
2018-06-15 |
2021-07-07 |
Shanghai Miracogen Inc. |
METHODS AND MATERIALS FOR TREATMENT OF CANCER
|
EP3808376A4
(en)
|
2018-06-17 |
2021-09-01 |
L&L Biopharma Co., Ltd. |
CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
|
CN112601553A
(zh)
|
2018-06-18 |
2021-04-02 |
拜耳股份有限公司 |
具有可酶切的接头和改善的活性谱的针对cxcr5的结合剂-药物缀合物
|
KR20210027436A
(ko)
|
2018-06-29 |
2021-03-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
|
UY38289A
(es)
|
2018-07-02 |
2020-01-31 |
Amgen Inc |
Proteína de unión al antígeno anti-steap1
|
CN112601522A
(zh)
*
|
2018-07-09 |
2021-04-02 |
辛瑟斯治疗股份有限公司 |
抗体-alk5抑制剂偶联物及其用途
|
WO2020014353A1
(en)
|
2018-07-11 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
|
CA3106520A1
(en)
|
2018-07-13 |
2020-01-16 |
Il-2Rx, Inc. |
Compounds, compositions, methods, and uses for treating cancer and immunological disorders
|
EA202190451A1
(ru)
|
2018-08-10 |
2021-07-13 |
Чугаи Сейяку Кабусики Кайся |
Анти-cd137 антигенсвязывающие молекулы и их применение
|
KR20210049122A
(ko)
|
2018-08-17 |
2021-05-04 |
메르사나 테라퓨틱스, 인코포레이티드 |
NaPi2b 표적화 폴리머 항체-약물 접합체 및 이것의 사용 방법
|
EP3849660A1
(en)
|
2018-09-12 |
2021-07-21 |
QuiaPEG Pharmaceuticals AB |
Releasable glp-1 conjugates
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
JP2022511337A
(ja)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3113058A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
CA3114137A1
(en)
|
2018-09-26 |
2020-04-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
|
CA3114349A1
(en)
|
2018-09-26 |
2020-04-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
BR112021005907A2
(pt)
|
2018-09-27 |
2021-08-10 |
Xilio Development, Inc. |
citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
|
CN112543771B
(zh)
|
2018-09-30 |
2023-04-11 |
江苏豪森药业集团有限公司 |
抗b7h3抗体-依喜替康类似物偶联物及其医药用途
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
WO2020076849A1
(en)
|
2018-10-11 |
2020-04-16 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
JP2022505101A
(ja)
*
|
2018-10-18 |
2022-01-14 |
ファンダメンタル ファーマ ゲーエムベーハー |
Nmda受容体媒介毒性を調節するための新規の方法
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
CA3117050A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
TW202034958A
(zh)
|
2018-10-30 |
2020-10-01 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
|
WO2020090979A1
(ja)
|
2018-10-31 |
2020-05-07 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
EP3877413A1
(en)
|
2018-11-06 |
2021-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2020112588A1
(en)
|
2018-11-30 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
|
JP2022513682A
(ja)
|
2018-11-30 |
2022-02-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd38免疫療法によりがんを処置するための組成物および方法
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
KR20210102334A
(ko)
|
2018-12-12 |
2021-08-19 |
브리스톨-마이어스 스큅 컴퍼니 |
트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
|
EP3894543A1
(en)
|
2018-12-14 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
WO2020127968A1
(en)
|
2018-12-20 |
2020-06-25 |
Marino Stephen F |
Protein-drug conjugate comprising a monomeric form of proteinase 3
|
AU2019406199A1
(en)
|
2018-12-21 |
2021-07-29 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibodies and uses thereof
|
AU2019416216A1
(en)
|
2018-12-26 |
2021-07-08 |
City Of Hope |
Activatable masked anti-CTLA4 binding proteins
|
EP3914291A2
(en)
|
2019-01-22 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Immunoglobulin a antibodies and methods of production and use
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
MA54863A
(fr)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
|
WO2020160156A2
(en)
|
2019-01-30 |
2020-08-06 |
Immutics, Inc. |
Anti-gal3 antibodies and uses thereof
|
EP3920968A1
(en)
|
2019-02-05 |
2021-12-15 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
WO2020181164A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
EP3938403A1
(en)
|
2019-03-14 |
2022-01-19 |
F. Hoffmann-La Roche AG |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
CA3134522A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
CA3136888A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
MX2021012961A
(es)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CN110283766B
(zh)
*
|
2019-05-13 |
2020-12-18 |
华中科技大学 |
一种重组卡介苗及其构建与应用
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
JP2022532282A
(ja)
|
2019-05-15 |
2022-07-14 |
中外製薬株式会社 |
抗原結合分子、薬学的組成物、および方法
|
WO2020243546A1
(en)
|
2019-05-30 |
2020-12-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
AR119097A1
(es)
|
2019-06-05 |
2021-11-24 |
Seattle Genetics Inc |
Métodos de purificación de anticuerpos enmascarados
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
TW202112398A
(zh)
|
2019-06-06 |
2021-04-01 |
大陸商上海翰森生物醫藥科技有限公司 |
抗b7-h4抗體-藥物偶聯物及其醫藥用途
|
AU2020289464A1
(en)
|
2019-06-06 |
2022-01-20 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
CN115135628A
(zh)
|
2019-06-17 |
2022-09-30 |
泰克沃尔科斯制药有限公司 |
快速高效点击释放的化合物
|
WO2020256721A1
(en)
|
2019-06-19 |
2020-12-24 |
Synthis, Llc |
Antib0dy-alk5 inhibitor conjugates and their uses
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
CA3145301A1
(en)
|
2019-07-08 |
2021-01-14 |
Imcare Biotech, Llc. |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
CR20220049A
(es)
|
2019-07-10 |
2022-03-02 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión a claudina-6 y usos de las mismas
|
US20220273809A1
(en)
|
2019-07-19 |
2022-09-01 |
Genmab A/S |
Axl antibody-drug conjugates for use in treating cancer
|
AU2020318975A1
(en)
|
2019-07-22 |
2022-03-17 |
Seagen Inc. |
Humanized anti-LIV1 antibodies for the treatment of cancer
|
AU2020322588A1
(en)
|
2019-07-30 |
2022-02-03 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
|
US20220289859A1
(en)
|
2019-08-06 |
2022-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmacuetical Compositions and Related Methods
|
JP7303298B2
(ja)
|
2019-08-07 |
2023-07-04 |
煙台邁百瑞国際生物医薬股▲ふん▼有限公司 |
抗体薬物複合体及びその応用
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
US20240043512A1
(en)
|
2019-09-11 |
2024-02-08 |
Imcare Biotech, Llc |
Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
|
WO2021055306A1
(en)
|
2019-09-16 |
2021-03-25 |
Bristol-Myers Squibb Company |
Dual capture method for analysis of antibody-drug conjugates
|
US20220411436A1
(en)
|
2019-09-18 |
2022-12-29 |
Sichuan Baili Pharmaceutical Co., Ltd |
Camptothecin derivative and conjugate thereof
|
WO2021055865A1
(en)
|
2019-09-19 |
2021-03-25 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
EP4036149A4
(en)
|
2019-09-26 |
2023-10-25 |
NOF Corporation |
HETEROBIFUNCTIONAL MONODISPERSPERED POLYETHYLENE GLYCOL WITH PEPTIDE LINKER
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
EP3828196A4
(en)
|
2019-09-29 |
2022-04-27 |
MabPlex International Co., Ltd. |
METHOD FOR PREPARING AN ANTIBODY-DRUG CONJUGATE INTERMEDIATE BY MEANS OF AN ACID METHOD AND USE THEREOF
|
AU2020357550A1
(en)
|
2019-10-04 |
2022-05-05 |
Tae Life Sciences, Llc |
Antibody compositions comprising Fc mutations and site-specific conjugation properties
|
CN115151564A
(zh)
|
2019-10-04 |
2022-10-04 |
思进股份有限公司 |
抗pd-l1抗体和抗体-药物缀合物
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
MX2022005400A
(es)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
RU2729192C1
(ru)
*
|
2019-11-22 |
2020-08-05 |
Общество с ограниченной ответственностью "Изварино Фарма" |
Конъюгат монометил ауристатина е для получения композиции для лечения рака предстательной железы
|
CN110964043B
(zh)
*
|
2019-12-02 |
2022-05-24 |
广州中医药大学(广州中医药研究院) |
一种瓜氨酸探针化合物及其应用
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
JP2023506187A
(ja)
|
2019-12-09 |
2023-02-15 |
シージェン インコーポレイテッド |
Liv1-adcおよびpd-1アンタゴニストとの併用療法
|
CN114650845B
(zh)
|
2019-12-12 |
2024-04-16 |
江苏恒瑞医药股份有限公司 |
抗密蛋白抗体药物偶联物及其医药用途
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
KR20220113747A
(ko)
|
2019-12-16 |
2022-08-16 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항 cea 항체-엑사테칸 유사체의 접합체 및 이의 약학적 용도
|
CA3158579A1
(en)
|
2019-12-18 |
2021-06-24 |
Pranjali DALVI |
Heavy chain antibodies binding to cd38
|
IL294226A
(en)
|
2019-12-27 |
2022-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibodies and their use
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
WO2021136223A1
(en)
|
2019-12-31 |
2021-07-08 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
JP2023509760A
(ja)
|
2020-01-08 |
2023-03-09 |
シンシス セラピューティクス,インコーポレイテッド |
Alk5阻害剤複合体およびその使用
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
KR20220130717A
(ko)
|
2020-01-22 |
2022-09-27 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항-trop-2 항체-엑사테칸 유사체 접합체 및 이의 의학적 용도
|
CN114845739A
(zh)
|
2020-01-22 |
2022-08-02 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
BR112022013795A2
(pt)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
Composição farmacêutica líquida, e, kit
|
EP4114852A1
(en)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
MX2022011156A
(es)
|
2020-03-13 |
2022-10-13 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos.
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
US11919948B2
(en)
|
2020-03-19 |
2024-03-05 |
Genentech, Inc. |
Isoform-selective anti-TGFβ antibodies and methods of use
|
CN115103858A
(zh)
|
2020-03-25 |
2022-09-23 |
江苏恒瑞医药股份有限公司 |
一种抗体药物偶联物的制备方法
|
JP2023519261A
(ja)
|
2020-03-25 |
2023-05-10 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗psma抗体-エキサテカン類似体複合体及びその医薬用途
|
CA3175733A1
(en)
|
2020-03-25 |
2021-09-30 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Pharmaceutical composition comprising antibody drug conjugate and use thereof
|
EP4126066A4
(en)
|
2020-03-27 |
2024-04-24 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
BR112022020332A2
(pt)
|
2020-04-10 |
2022-12-13 |
Seagen Inc |
Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
CA3177562A1
(en)
|
2020-05-03 |
2021-11-11 |
Tong Zhu |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
US20230302050A1
(en)
|
2020-05-20 |
2023-09-28 |
Institut Curie |
Single Domain Antibodies and Their Use in Cancer Therapies
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
US20230226207A1
(en)
|
2020-06-08 |
2023-07-20 |
Sichuan Baili Pharm Co., Ltd |
Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof
|
EP4163294A1
(en)
|
2020-06-09 |
2023-04-12 |
Ajinomoto Co., Inc. |
Modified ferritin and method for producing same
|
JP2023529203A
(ja)
|
2020-06-11 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
ナノリポタンパク質-ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
TW202200616A
(zh)
|
2020-06-18 |
2022-01-01 |
美商建南德克公司 |
使用抗tigit抗體及pd-1軸結合拮抗劑之治療
|
CA3171101A1
(en)
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
AU2021299947A1
(en)
|
2020-06-29 |
2022-12-22 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
JP2023533735A
(ja)
|
2020-07-10 |
2023-08-04 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
スルホニルベンズアミド系誘導体及びその複合体、その調製方法並びにその応用
|
CN115812149A
(zh)
|
2020-07-13 |
2023-03-17 |
基因泰克公司 |
用于预测多肽免疫原性的基于细胞的方法
|
CN116249556A
(zh)
|
2020-07-21 |
2023-06-09 |
基因泰克公司 |
降解brm的抗体缀合化学诱导剂及其方法
|
BR112023001359A2
(pt)
|
2020-07-27 |
2023-02-14 |
Tuojie Biotech Shanghai Co Ltd |
Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
|
EP4190801A1
(en)
|
2020-07-29 |
2023-06-07 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring pharmacokinetics of drug labeled with non-radioactive substance
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
WO2022031652A1
(en)
|
2020-08-04 |
2022-02-10 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
JP2023537683A
(ja)
|
2020-08-07 |
2023-09-05 |
ジェネンテック, インコーポレイテッド |
ポリペプチド免疫原性を予測するためのt細胞ベースの方法
|
TW202221016A
(zh)
|
2020-08-07 |
2022-06-01 |
美商建南德克公司 |
Flt3配位體融合蛋白及使用方法
|
CN112062855A
(zh)
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
TW202229344A
(zh)
|
2020-09-21 |
2022-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
抗-cd40抗體用於治療發炎病況之用途
|
US20220112274A1
(en)
|
2020-09-28 |
2022-04-14 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
JP2023545684A
(ja)
|
2020-09-30 |
2023-10-31 |
ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド |
ポリペプチドコンジュゲートおよび使用の方法
|
US20240024498A1
(en)
|
2020-09-30 |
2024-01-25 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230381332A1
(en)
|
2020-10-12 |
2023-11-30 |
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof
|
AU2021359457A1
(en)
|
2020-10-12 |
2023-05-11 |
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
Camptothecin derivative and its ligand-drug conjugate
|
CA3196940A1
(en)
|
2020-10-14 |
2022-04-21 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
JP2023516111A
(ja)
|
2020-10-27 |
2023-04-18 |
エルシダ オンコロジー, インコーポレイテッド |
ナノ粒子を官能化する方法
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
CN116801898A
(zh)
|
2020-11-05 |
2023-09-22 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
TW202233248A
(zh)
|
2020-11-08 |
2022-09-01 |
美商西健公司 |
組合療法
|
CN112402616A
(zh)
*
|
2020-11-23 |
2021-02-26 |
荣昌生物制药(烟台)股份有限公司 |
一种含环丙沙星和抗体药物偶联物的药物组合物及其应用
|
CN114524878A
(zh)
|
2020-11-23 |
2022-05-24 |
康诺亚生物医药科技(成都)有限公司 |
一种双特异性抗体及其用途
|
IL303059A
(en)
*
|
2020-11-24 |
2023-07-01 |
Novartis Ag |
Antibodies against CD48, antibody-drug conjugates and uses thereof
|
KR20230112656A
(ko)
|
2020-11-25 |
2023-07-27 |
이나뜨 파르마 에스.에이. |
암의 치료
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
CN114685657A
(zh)
|
2020-12-31 |
2022-07-01 |
康诺亚生物医药科技(成都)有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
IL304031A
(en)
|
2021-01-14 |
2023-08-01 |
Inst Curie |
Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
|
WO2022154127A1
(ja)
|
2021-01-18 |
2022-07-21 |
味の素株式会社 |
化合物またはその塩、およびそれらにより得られる抗体
|
CN116829573A
(zh)
|
2021-01-18 |
2023-09-29 |
味之素株式会社 |
化合物或其盐、及由它们得到的抗体
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024504390A
(ja)
|
2021-01-22 |
2024-01-31 |
バイワンキュア セラピューティクス, インコーポレイテッド |
抗her-2/trop-2構築物及びその使用
|
EP4284838A2
(en)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
WO2022166779A1
(zh)
|
2021-02-04 |
2022-08-11 |
上海森辉医药有限公司 |
糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
|
TW202302626A
(zh)
|
2021-02-15 |
2023-01-16 |
日商武田藥品工業股份有限公司 |
用於調節tgf-b信息傳導之細胞療法組成物及方法
|
JP2024506590A
(ja)
|
2021-02-16 |
2024-02-14 |
グリコス・フィンランド・オーワイ |
リンカー-ペイロードおよびそのコンジュゲート
|
AU2022230384A1
(en)
|
2021-03-01 |
2023-09-07 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
JP2024508976A
(ja)
|
2021-03-08 |
2024-02-28 |
ジーンクアンタム ヘルスケア (スーチョウ) シーオー., エルティーディー. |
抗体-免疫アゴニストコンジュゲート及びその使用
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
AU2022234694A1
(en)
|
2021-03-11 |
2023-09-21 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained using same
|
JPWO2022196675A1
(pl)
|
2021-03-16 |
2022-09-22 |
|
|
US20230091653A1
(en)
|
2021-03-18 |
2023-03-23 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
TW202300179A
(zh)
|
2021-03-18 |
2023-01-01 |
美商西根公司 |
內化的生物活性化合物偶聯物選擇性釋放藥物
|
WO2022200303A1
(en)
|
2021-03-23 |
2022-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
CN117396504A
(zh)
|
2021-03-30 |
2024-01-12 |
拜耳公司 |
抗Sema3A抗体及其用途
|
WO2023178641A1
(zh)
|
2022-03-25 |
2023-09-28 |
成都百利多特生物药业有限责任公司 |
一种dna毒性二聚体化合物及其偶联物
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
EP4323009A1
(en)
|
2021-04-14 |
2024-02-21 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Linkers, conjugates and applications thereof
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
CN116917324A
(zh)
|
2021-04-26 |
2023-10-20 |
江苏恒瑞医药股份有限公司 |
抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
KR20240012381A
(ko)
*
|
2021-05-19 |
2024-01-29 |
바이오하벤 테라퓨틱스 리미티드 |
세포독성제를 전달하기 위한 mate 기술을 사용한 항체 약물 접합체
|
CN117321219A
(zh)
|
2021-05-19 |
2023-12-29 |
中外制药株式会社 |
预测分子的体内药代动力学的方法
|
BR112023023831A2
(pt)
|
2021-05-26 |
2024-01-30 |
Oxford Biotherapeutics Ltd |
Métodos, combinação farmacêutica, anticorpo ou porção de ligação ao antígeno do mesmo
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
KR20240024213A
(ko)
|
2021-06-25 |
2024-02-23 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체
|
WO2022270612A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体の使用
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
KR20230015301A
(ko)
|
2021-07-19 |
2023-01-31 |
맙플렉스 인터내셔널 컴퍼니 리미티드 |
2성분 독소가 부하된 항체-약물 접합체 및 그의 용도
|
US11806405B1
(en)
|
2021-07-19 |
2023-11-07 |
Zeno Management, Inc. |
Immunoconjugates and methods
|
WO2023001248A1
(zh)
|
2021-07-21 |
2023-01-26 |
江苏恒瑞医药股份有限公司 |
一种含抗trop2抗体药物偶联物的药物组合物及其用途
|
CN117460540A
(zh)
|
2021-07-22 |
2024-01-26 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物
|
KR20240040786A
(ko)
|
2021-08-03 |
2024-03-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
|
WO2023019092A1
(en)
|
2021-08-07 |
2023-02-16 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2023031366A1
(en)
|
2021-09-02 |
2023-03-09 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Anti-cecam6 antibodies with reduced side-effects
|
CA3230737A1
(en)
|
2021-09-03 |
2023-03-09 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
WO2023041717A1
(en)
|
2021-09-16 |
2023-03-23 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
AU2022345098A1
(en)
|
2021-09-16 |
2024-04-04 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
AU2022357933A1
(en)
|
2021-09-30 |
2024-04-11 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023054714A1
(ja)
|
2021-09-30 |
2023-04-06 |
味の素株式会社 |
抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
|
WO2023051814A1
(zh)
|
2021-09-30 |
2023-04-06 |
江苏恒瑞医药股份有限公司 |
吡咯并苯并二氮杂卓类衍生物及其偶联物、其制备方法及其应用
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023081230A1
(en)
*
|
2021-11-03 |
2023-05-11 |
Adcentrx Therapeutics Inc. |
Novel auristatin analogs and immunoconjugates thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
TW202340226A
(zh)
|
2021-12-17 |
2023-10-16 |
德商3B製藥有限公司 |
碳酸酐酶ix配位體
|
WO2023122347A2
(en)
|
2021-12-23 |
2023-06-29 |
Mirecule, Inc. |
Compositions for delivery of polynucleotides
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023147329A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation and methods thereof
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023158305A1
(en)
|
2022-02-15 |
2023-08-24 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
TW202346365A
(zh)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及化學療法之組合治療
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
US20230406930A1
(en)
|
2022-04-13 |
2023-12-21 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023215293A1
(en)
|
2022-05-02 |
2023-11-09 |
Athanor Biosciences, Inc. |
Cancer eradicating – bio-nanoparticles (ce-bnp)
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023227660A1
(en)
|
2022-05-25 |
2023-11-30 |
Innate Pharma |
Nectin-4 binding agents
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
US20240108744A1
(en)
*
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
CN116284202A
(zh)
*
|
2023-03-28 |
2023-06-23 |
华侨大学 |
白桦脂酸的PROTACs化合物及其制备方法和应用
|